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Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the 
third most common cause of cancer mortality. As for many other tumors, development 
of HCC is due to a multistep process with accumulation of genetic and epigenetic 
alterations in regulatory genes, leading to activation of oncogenes and inactivation or 
loss of tumor suppressor genes. Substantial changes of DNA methylation at a 
genome-wide level were observed in HCC. Understanding epigenetic changes in HCC 
will help to elucidate the pathogenesis and may eventually lead to identification of 
molecular markers for liver cancer diagnosis, treatment and prognosis. 
Human CHD5 had previously been proposed to function as a chromatin remodeling 
protein based on its homology with members of the chromodomain superfamily of 
proteins(1). CHD5 is one of nine members of the CHD family, named because of its 
unique combination of Chromo (chromatin organizing modulator) helicase and DNA 
binding domains. The chromodomain and helicase-like domain proteins are involved 
in regulating chromatin architecture and are able to modify chromatin structure in an 
ATP-dependent manner. They are characterized by the presence of two 
amino-terminal chromodomains, which interact with methylated histone tails. The 
histone modifications have been shown to play key roles in regulating gene 
transcription, particularly in cancer.CHD3 and CHD4 are components of the 
nucleosome remodelling complex, an assembly of proteins that remodels chromatin 
by sliding nucleosomes out of the way,thereby providing polymerase with the access 
needed to activate gene expression.CHD3 and CHD4 have been shown to be involved 
in human diseases. CHD5 is similar to CHD3 and CHD4 in that it is endowed with 
plant homeodomain (PHD) motifs. Many studies have shown that CHD genes have a 
wide range of functions and play key roles in transcriptional elongation, Furthermore, 
the regulation of their own expression has previously received much attention. The 
1p36.3 chromosome is frequently deleted in a range of human cancers, including 
neuroblastoma, meningioma, melanoma, hematopoietic malignancies, 
oligodendroglioma, and pheochromocytoma, as well as in epithelial malignancies 
















loss of tumor suppressor mapping to this region is critical for tumorigenesis. Further 
investigations have demonstrated that CHD5 is located in the smallest region of 
deletion 1p36.31 in neuroblastomas generated mouse models with gain and loss of a 
region corresponding to the region of human 1p36.3 chromosome containing mouse 
Chd5 by chromosome engineering. It was shown that heterozygosity of the region 
encompassing CHD5 predisposes to spontaneous tumors, and specific CHD5 
depletion enhances tumor growth in nude mice. Furthermore, mouse CHD5 was 
identified as a tumor suppressor that controls proliferation, apoptosis, and senescence 
via the p19Arf/p53 pathway.Identification of Chd5 as a tumor suppressor in the mouse 
agrees with the rich body of literature describing 1p36 deletions in various human 
cancers; many of which encompass CHD5. These 1p36.31 deletions may cause the 
low expression of CHD5 observed in these human cancers. In Furthermore, CHD5 
was inactivated through the transcriptional repression mediated by JMJD2A. 
   Investigation of the regulatory mechanism underlying aberrant CHD5 expression 
in cancers is of crucial importance. .The expression profile and function of CHD5 in 
HCC remain obscure. Given CHD5’s pivotal role in cancer, we hypothesize that 
CHD5 is inactivated in HCC and sought to elucidate its mechanism of the inactivation 
and functions. In this study, we investigated the expression of the CHD5 gene in HCC 
tissues by RealTime PCR and Western blot (WB)and the results shows that the CHD5 
protein expression in tumor tissues were significantly downregulated.To investigate 
the function of CHD5 protein, we down-regulated the expression of CHD5 protein in 
HCC cell line  HepG2  with  plasmid-based CHD5 shRNA  and the results shows 
that the downregulated of CHD5 protein promotes the maligant phenotype  of  
hepatoma cell .Furthermore ,we found that CHD5 protein can regulate EMT markers 
like E-cadherin、Vimentin、Fibronectin…,  
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肝细胞性肝癌(hepatocellular carcinoma, HCC)是全球常见的恶性肿瘤之一, 








发病率较低. 需指出的是, 中国新发肝癌病例数占全球总数的 40％, 每年新发
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